CNBC Halftime Report Final Trades: Charles Schwab, Cleveland-Cliffs, UnitedHealth Group, Incyte

GLJ Research Reiterates Buy on Cleveland-Cliffs, Maintains $15.6 Price Target

GLJ Research analyst Gordon L. Johnson reiterates Cleveland-Cliffs (NYSE:CLF) with a Buy and maintains $15.6 price target.

Shares of copper-linked companies are trading higher on rising Chinese demand, after the Yangshan copper premium reached its highest level since October 2022. Supply issues and U.S. tariff concerns have contributed to recent strength.

Charles Schwab, UnitedHealth And Cleveland-Cliffs: CNBC’s ‘Final Trades’

CNBC final trades: Pros picked Schwab, Cleveland-Cliffs, UnitedHealth and Incyte; shares posted mixed moves Wednesday.

This Small Biotech’s Cancer Drug Could Reach $1.3 Billion In Peak Sales

William Blair initiates Zentalis (ZNTL) at Outperform, citing a $1.3B peak sales potential for lead cancer drug azenosertib.

Incyte Announces Agreement With CMS To Offer Jakafi And Jakafi XR To State Medicaid Programs At Prices Aligned With Other Industrialized Nations; Says It Does Not Expect Impact To 2026 Guidance

The Federal Reserve Just Raised Interest Rates for the First Time Since 2023. Here's What History Says Happens in the Stock Market Next.

The Federal Reserve, under Chairman Kevin Warsh, raised the federal funds rate by a quarter point in response to persistent inflation. Historically, rate-hiking cycles have triggered an average 14% drawdown in the S&P 500 within 12 months, though stocks typically recover within a year with an average 6% return. The impact will be most severe on growth stocks and debt-dependent companies, but unless underlying earnings falter, the bull market should eventually resume.